PL2374819T3 - Przeciwciała przeciwko MASP-2 - Google Patents

Przeciwciała przeciwko MASP-2

Info

Publication number: PL2374819T3
Authority: PL; Poland
Prior art keywords: masp; antibodies
Prior art date: 2003-05-12

Application number

PL11172040T

Other languages

English (en)

Inventor

Flemming Larsen

Ulla Wahlers

Original Assignee

Helion Biotech Aps

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-05-12

Filing date

2004-05-12

Publication date

2017-09-29

2004-05-12 Application filed by Helion Biotech Aps filed Critical Helion Biotech Aps

2017-09-29 Publication of PL2374819T3 publication Critical patent/PL2374819T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Cardiology (AREA)
Physical Education & Sports Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Transplantation (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

PL11172040T 2003-05-12 2004-05-12 Przeciwciała przeciwko MASP-2 PL2374819T3 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DKPA200300716		2003-05-12

Publications (1)

Publication Number	Publication Date
PL2374819T3 true PL2374819T3 (pl)	2017-09-29

Family

ID=33483731

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL04732276T PL1625166T3 (pl)	2003-05-12	2004-05-12	Przeciwciała przeciwko masp-2
PL11172040T PL2374819T3 (pl)	2003-05-12	2004-05-12	Przeciwciała przeciwko MASP-2

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL04732276T PL1625166T3 (pl)	2003-05-12	2004-05-12	Przeciwciała przeciwko masp-2

Country Status (11)

Country	Link
US (8)	US9096676B2 (pl)
EP (2)	EP2374819B1 (pl)
CN (1)	CN1798769A (pl)
CY (2)	CY1116506T1 (pl)
DK (2)	DK2374819T3 (pl)
ES (2)	ES2541134T3 (pl)
HU (2)	HUE024996T2 (pl)
PL (2)	PL1625166T3 (pl)
PT (2)	PT2374819T (pl)
SI (2)	SI2374819T1 (pl)
WO (1)	WO2004106384A1 (pl)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6969601B2 (en)	1997-04-03	2005-11-29	Jensenius Jens Chr	MASP-2, a complement-fixing enzyme, and uses for it
PT2374819T (pt)	2003-05-12	2017-07-04	Helion Biotech Aps	Anticorpos para masp-2
US8840893B2 (en)	2004-06-10	2014-09-23	Omeros Corporation	Methods for treating conditions associated with MASP-2 dependent complement activation
AU2013201565B2 (en) *	2004-06-10	2016-03-31	Omeros Corporation	Methods for treating conditions associated with MASP-2-dependent complement activation
AU2011265532B2 (en) *	2004-06-10	2014-04-24	Omeros Corporation	Methods for treating conditions associated with MASP-2-dependent complement activation
GB0412966D0 (en) *	2004-06-10	2004-07-14	Univ Leicester	Genetically modified non-human mammals and cells
US7919094B2 (en) *	2004-06-10	2011-04-05	Omeros Corporation	Methods for treating conditions associated with MASP-2 dependent complement activation
PL2465534T3 (pl) *	2004-06-10	2017-08-31	Omeros Corporation	Sposoby leczenia stanów związanych z aktywacją dopełniacza zależną od masp-2
WO2005123776A1 (en) *	2004-06-10	2005-12-29	Omeros Corporation	Methods for treating conditions associated with lectin-dependent complement activation
US8859209B2 (en)	2006-01-12	2014-10-14	Carviar Aps	Reimmunization and antibody design
US8524453B2 (en) *	2006-02-10	2013-09-03	The Brigham And Woman's Hospital, Inc.	Lectin complement pathway assays and related compositions and methods
EP2463306A1 (en)	2006-05-02	2012-06-13	Carviar ApS	Method for immunizing an avian species
KR101603917B1 (ko) *	2008-05-09	2016-03-17	애브비 인코포레이티드	최종 당화 산물의 수용체(ｒａｇｅ)에 대한 항체 및 이의 용도
CN106390117A (zh) *	2009-10-16	2017-02-15	奥默罗斯公司	通过抑制masp‑2依赖性补体活化治疗弥散性血管内凝血的方法
KR20220044616A (ko)	2011-04-08	2022-04-08	유니버시티 오브 레스터	Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법
US9644035B2 (en)	2011-04-08	2017-05-09	Omeros Corporation	Methods for treating conditions associated with MASP-2 dependent complement activation
AU2013201779B2 (en) *	2011-05-04	2016-01-07	Omeros Corporation	Compositions for inhibiting MASP-2 dependent complement activation
EP2704743B1 (en) *	2011-05-04	2020-03-11	Omeros Corporation	Compositions for inhibiting masp-2 dependent complement acitivation
US20140363433A1 (en)	2013-03-15	2014-12-11	Omeros Corporation	Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
US20150017162A1 (en) *	2013-03-15	2015-01-15	Omeros Corporation	Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
CN103614341B (zh) *	2013-09-02	2016-07-13	杨旸	抗甘露糖结合凝聚素的单克隆抗体及试剂盒
WO2015058143A1 (en)	2013-10-17	2015-04-23	Omeros Corporation	Methods for treating conditions associated with masp-2 dependent complement activation
US10359743B2 (en) *	2014-11-25	2019-07-23	Applied Materials, Inc.	Substrate processing systems, apparatus, and methods with substrate carrier and purge chamber environmental controls
CN117503923A (zh)	2016-01-05	2024-02-06	莱斯特大学	用于抑制有需要的受试者的纤维化的方法
WO2017173290A1 (en)	2016-03-31	2017-10-05	Omeros Corporation	Methods for inhibiting angiogenesis in a subject in need thereof
JOP20190068A1 (ar) *	2016-10-13	2019-04-01	Omeros Corp	طرق لتقليل البول البروتيني في خاضع بشري يعاني من الاعتلال الكلوي a الناتج عن الجلوبيولين المناعي
US11007254B2 (en)	2016-10-17	2021-05-18	Musc Foundation For Research Development	Compositions and methods for treating central nervous system injury
TWI881481B (zh)	2017-08-15	2025-04-21	美商歐米諾斯公司	用於治療和／或預防與造血幹細胞移植有關的移植物抗宿主病和／或瀰漫性肺泡出血和／或靜脈閉塞性病的方法
MA53234A (fr) *	2018-06-22	2022-04-20	Omeros Corp	Compositions et procédés d'inhibition de masp-2 pour le traitement de divers troubles et maladies thrombotiques
GB2583560A (en)	2018-12-11	2020-11-04	Admirx Inc	Fusion protein constructs for complement associated disease
SG11202111587VA (en)	2019-05-07	2021-11-29	Bayer Ag	Masp inhibitory compounds and uses thereof
TWI867422B (zh)	2020-03-06	2024-12-21	美商奥默羅斯公司	用於治療和/或預防流感病毒誘導的急性呼吸窘迫症候群、肺炎或者流感病毒感染的一些其它肺部表現的抑制masp-2的方法
EP4240750A1 (en)	2020-11-04	2023-09-13	Bayer Aktiengesellschaft	Masp inhibitory compounds and uses thereof
EP4011904A1 (en)	2020-12-14	2022-06-15	Bayer Aktiengesellschaft	Masp inhibitory compounds and uses thereof
CN115215937B (zh)	2021-04-15	2023-05-26	上海麦济生物技术有限公司	抗人masp-2抗体及其制备方法和应用
IL309231A (en) *	2021-06-08	2024-02-01	Shanghai Jemincare Pharmaceuticals Co Ltd	ANTI-MASP-2 antibody and its use
WO2023274340A1 (en) *	2021-06-30	2023-01-05	Suzhou Transcenta Therapeutics Co., Ltd.	Novel anti-masp-2 antibodies
WO2023103789A1 (zh) *	2021-12-10	2023-06-15	舒泰神（北京）生物制药股份有限公司	特异性识别masp2的抗体及其应用
EP4493597A1 (en) *	2022-03-18	2025-01-22	Inmagene Pte. Ltd.	Masp-2-targetting antibodies and uses thereof
US12216123B2 (en)	2023-04-25	2025-02-04	Nuvance Health	Extracellular vesicle derived MASP-2 directed cancer treatment methods
WO2025153000A1 (zh) *	2024-01-17	2025-07-24	信立泰(成都)生物技术有限公司	一种抗masp2抗体或其抗原结合片段及用途

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US558767A (en)		1896-04-21		Oyster-dredger
US4331647A (en)	1980-03-03	1982-05-25	Goldenberg Milton David	Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4394370A (en)	1981-09-21	1983-07-19	Jefferies Steven R	Bone graft material for osseous defects and method of making same
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4526909A (en)	1984-01-09	1985-07-02	Regents Of The University Of California	Polymethylmethacrylate delivery system for bone morphogenetic protein
US4563489A (en)	1984-02-10	1986-01-07	University Of California	Biodegradable organic polymer delivery system for bone morphogenetic protein
JPS6147500A (ja)	1984-08-15	1986-03-07	Res Dev Corp Of Japan	キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en)	1984-08-27	1987-11-25	The Board Of Trustees Of The Leland Stanford Junior University	Chimeric receptors by dna splicing and expression
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
JPH0662679B2 (ja)	1985-06-21	1994-08-17	新田ゼラチン株式会社	組織親和性コラ−ゲンとその製法
US5453566A (en)	1986-03-28	1995-09-26	Calgene, Inc.	Antisense regulation of gene expression in plant/cells
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US5554372A (en)	1986-09-22	1996-09-10	Emory University	Methods and vaccines comprising surface-active copolymers
US5270199A (en)	1987-08-20	1993-12-14	The Children's Medical Center Corporation	Human mannose-binding protein
MC2115A1 (fr)	1987-12-15	1991-07-05	Gene Shears Pty Ltd	Ribozynes
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
GB8822492D0 (en)	1988-09-24	1988-10-26	Considine J	Apparatus for removing tumours from hollow organs of body
US5211657A (en)	1988-11-07	1993-05-18	The United States Government As Represented By The Secretary Of The Department Of Health And Human Services	Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5549910A (en)	1989-03-31	1996-08-27	The Regents Of The University Of California	Preparation of liposome and lipid complex compositions
JP3218637B2 (ja)	1990-07-26	2001-10-15	大正製薬株式会社	安定なリポソーム水懸濁液
US5789573A (en)	1990-08-14	1998-08-04	Isis Pharmaceuticals, Inc.	Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
JP2958076B2 (ja)	1990-08-27	1999-10-06	株式会社ビタミン研究所	遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
EP0590058B1 (en)	1991-06-14	2003-11-26	Genentech, Inc.	HUMANIZED Heregulin ANTIBODy
IL108367A0 (en)	1993-01-27	1994-04-12	Hektoen Inst For Medical Resea	Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
US5801154A (en)	1993-10-18	1998-09-01	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide modulation of multidrug resistance-associated protein
DK1231268T3 (da)	1994-01-31	2005-11-21	Univ Boston	Polyklonale antistofbiblioteker
US5856121A (en)	1994-02-24	1999-01-05	Case Western Reserve University	Growth arrest homebox gene
JPH07238100A (ja)	1994-02-25	1995-09-12	Sumitomo Electric Ind Ltd	ヒトのｍａｓｐに対するモノクローナル抗体
US5741516A (en)	1994-06-20	1998-04-21	Inex Pharmaceuticals Corporation	Sphingosomes for enhanced drug delivery
US6492332B1 (en)	1995-12-12	2002-12-10	Omeros Corporation	Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
AU4467396A (en)	1994-12-12	1996-07-10	Omeros Medical Systems, Inc.	Irrigation solution and method for inhibition of pain, inflammation and spasm
US5795587A (en)	1995-01-23	1998-08-18	University Of Pittsburgh	Stable lipid-comprising drug delivery complexes and methods for their production
US5738868A (en)	1995-07-18	1998-04-14	Lipogenics Ltd.	Liposome compositions and kits therefor
US5739119A (en)	1996-11-15	1998-04-14	Galli; Rachel L.	Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA
US6008017A (en)	1997-01-02	1999-12-28	Smithkline Beecham Corporation	Human cardiac/brain tolloid-like protein
US6969601B2 (en)	1997-04-03	2005-11-29	Jensenius Jens Chr	MASP-2, a complement-fixing enzyme, and uses for it
US5955309A (en)	1997-06-18	1999-09-21	Smithkline Beecham Corporation	Polynucleotide encoding G-protein coupled receptor (H7TBA62)
US6297024B1 (en)	1998-10-15	2001-10-02	Cell Activation, Inc.	Methods for assessing complement activation
EP1140171A4 (en)	1998-12-15	2002-03-13	Brigham & Womens Hospital	METHODS AND PRODUCTS FOR REGULATING THE COMPLEMENT ACTIVATION ASSOCIATED WITH THE LECTIN COMPLEMENT SYSTEM
US7273925B1 (en)	1998-12-15	2007-09-25	Brigham And Women's Hospital, Inc.	Methods and products for regulating lectin complement pathway associated complement activation
US6235494B1 (en)	1999-02-08	2001-05-22	The Scripps Research Institute	Substrates for assessing mannan-binding protein-associated serine protease activity and methods using the substrates
CA2296792A1 (en)	1999-02-26	2000-08-26	Genset S.A.	Expressed sequence tags and encoded human proteins
AU3395900A (en)	1999-03-12	2000-10-04	Human Genome Sciences, Inc.	Human lung cancer associated gene sequences and polypeptides
WO2000058362A1 (en)	1999-03-26	2000-10-05	Human Genome Sciences, Inc.	Neutrokine-alpha binding proteins and methods based thereon
AU781135B2 (en)	1999-05-14	2005-05-05	Thomas Vorup Jensen	Recombinant human mannan-binding lectin
EP2322226A3 (en)	1999-07-21	2011-08-17	Omeros Corporation	Solutions and methods for inhibition of pain, inflammation and cartilage degradation
WO2001010902A2 (en)	1999-08-11	2001-02-15	Curagen Corporation	Nucleoc acids and secreted polypeptides encoded thereby
WO2001012212A1 (en)	1999-08-13	2001-02-22	The Brigham And Women's Hospital, Inc.	Inhibitors of the lectin complement pathway (lcp) and their use
AU785149B2 (en)	1999-12-02	2006-10-05	Jens Christian Jensenius	MASP-3, a complement-fixing enzyme, and uses for it
US6649592B1 (en)	2000-01-14	2003-11-18	Science & Technology Corporation @ Unm	Peptide inhibitors of LFA-1/ICAM-1 interaction
EP2026073B1 (en)	2000-04-29	2016-03-30	University Of Iowa Research Foundation	Diagnostics and therapeutics for macular degeneration-related disorders
SG98393A1 (en)	2000-05-19	2003-09-19	Inst Materials Research & Eng	Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
WO2002006460A2 (en)	2000-07-13	2002-01-24	Jens Christian Jensenius	Masp-2, a complement-fixing enzyme, and uses for it
US20020094332A1 (en)	2001-01-18	2002-07-18	Alexion Pharmaceuticals	Method of prophylaxis against large myocardial infractions
US20030049260A1 (en)	2001-07-26	2003-03-13	Leonard Bell	Method of improving cognitive function
WO2003061765A1 (en)	2002-01-22	2003-07-31	Alexion Pharmaceuticals, Inc.	Method of prophylaxis against large myocardial infarctions
KR20040094413A (ko)	2002-02-01	2004-11-09	오메로스 코포레이션	연골 분해를 전신 억제하기 위한 조성물 및 방법
US7538195B2 (en) *	2002-06-14	2009-05-26	Immunogen Inc.	Anti-IGF-I receptor antibody
WO2004009664A2 (en)	2002-07-19	2004-01-29	Omeros Corporation	Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from
EP1545611B1 (en)	2002-09-06	2016-11-09	Alexion Pharmaceuticals, Inc.	Method of treatment of asthma using antibodies to complement component c5
US20060275764A1 (en)	2002-12-03	2006-12-07	Aarhus Universitet	Method for determining predisposition to manifestation of immune system related diseases
US7361339B2 (en)	2003-01-09	2008-04-22	Alexion Pharmaceuticals, Inc.	Methods for reducing morality associated with acute myocardial infarction
WO2004075837A2 (en)	2003-02-21	2004-09-10	Tanox, Inc.	Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
PT2374819T (pt)	2003-05-12	2017-07-04	Helion Biotech Aps	Anticorpos para masp-2
US7482376B2 (en)	2003-07-03	2009-01-27	3-Dimensional Pharmaceuticals, Inc.	Conjugated complement cascade inhibitors
WO2005014849A2 (en)	2003-07-03	2005-02-17	Euro-Celtique, S.A.	Genes associated with responses to neuropathic pain
EP1670910A1 (en)	2003-09-05	2006-06-21	Natimmune A/S	Masp-2 crystal structure and uses thereof
ES2526343T3 (es) *	2004-06-03	2015-01-09	Novimmune Sa	Anticuerpos anti-CD3 y métodos de uso de los mismos
WO2005123776A1 (en)	2004-06-10	2005-12-29	Omeros Corporation	Methods for treating conditions associated with lectin-dependent complement activation
GB0412966D0 (en)	2004-06-10	2004-07-14	Univ Leicester	Genetically modified non-human mammals and cells
PL2465534T3 (pl)	2004-06-10	2017-08-31	Omeros Corporation	Sposoby leczenia stanów związanych z aktywacją dopełniacza zależną od masp-2
MY161894A (en) *	2006-09-08	2017-05-15	Abbvie Bahamas Ltd	Interleukin-13 binding proteins

2004
- 2004-05-12 PT PT111720405T patent/PT2374819T/pt unknown
- 2004-05-12 ES ES04732276.3T patent/ES2541134T3/es not_active Expired - Lifetime
- 2004-05-12 WO PCT/DK2004/000338 patent/WO2004106384A1/en not_active Ceased
- 2004-05-12 EP EP11172040.5A patent/EP2374819B1/en not_active Expired - Lifetime
- 2004-05-12 PL PL04732276T patent/PL1625166T3/pl unknown
- 2004-05-12 CN CNA2004800155204A patent/CN1798769A/zh active Pending
- 2004-05-12 DK DK11172040.5T patent/DK2374819T3/en active
- 2004-05-12 HU HUE04732276A patent/HUE024996T2/en unknown
- 2004-05-12 US US10/556,509 patent/US9096676B2/en active Active
- 2004-05-12 SI SI200432396T patent/SI2374819T1/sl unknown
- 2004-05-12 PT PT47322763T patent/PT1625166E/pt unknown
- 2004-05-12 EP EP04732276.3A patent/EP1625166B1/en not_active Expired - Lifetime
- 2004-05-12 SI SI200432248T patent/SI1625166T1/sl unknown
- 2004-05-12 HU HUE11172040A patent/HUE034760T2/en unknown
- 2004-05-12 PL PL11172040T patent/PL2374819T3/pl unknown
- 2004-05-12 ES ES11172040.5T patent/ES2629344T3/es not_active Expired - Lifetime
- 2004-05-12 DK DK04732276.3T patent/DK1625166T3/en active
2015
- 2015-06-19 US US14/745,247 patent/US10189909B2/en not_active Expired - Lifetime
- 2015-07-02 CY CY20151100572T patent/CY1116506T1/el unknown
2017
- 2017-06-22 CY CY20171100658T patent/CY1119106T1/el unknown
2018
- 2018-12-04 US US16/209,255 patent/US11008404B2/en not_active Expired - Fee Related
2020
- 2020-01-07 US US16/736,626 patent/US11008405B2/en not_active Expired - Fee Related
- 2020-02-20 US US16/796,179 patent/US20200199252A1/en not_active Abandoned
2021
- 2021-02-22 US US17/181,983 patent/US11225526B2/en not_active Expired - Lifetime
- 2021-03-16 US US17/203,396 patent/US20210221913A1/en not_active Abandoned
2022
- 2022-06-28 US US17/851,944 patent/US20230058435A1/en not_active Abandoned

Also Published As

Publication number	Publication date
SI2374819T1 (sl)	2017-09-29
WO2004106384A1 (en)	2004-12-09
DK1625166T3 (en)	2015-07-13
US11008404B2 (en)	2021-05-18
US20190144564A1 (en)	2019-05-16
HUE034760T2 (en)	2018-02-28
EP2374819A1 (en)	2011-10-12
US9096676B2 (en)	2015-08-04
CY1116506T1 (el)	2017-03-15
ES2629344T3 (es)	2017-08-08
PL1625166T3 (pl)	2015-08-31
US20210261688A1 (en)	2021-08-26
PT1625166E (pt)	2015-08-20
EP1625166B1 (en)	2015-04-08
US11225526B2 (en)	2022-01-18
CY1119106T1 (el)	2018-02-14
US10189909B2 (en)	2019-01-29
EP2374819B1 (en)	2017-03-22
US20200216566A1 (en)	2020-07-09
HUE024996T2 (en)	2016-01-28
SI1625166T1 (sl)	2015-08-31
US20210221913A1 (en)	2021-07-22
US20200199252A1 (en)	2020-06-25
PT2374819T (pt)	2017-07-04
US20070009528A1 (en)	2007-01-11
US20160096897A1 (en)	2016-04-07
EP1625166A1 (en)	2006-02-15
DK2374819T3 (en)	2017-06-06
US11008405B2 (en)	2021-05-18
US20230058435A1 (en)	2023-02-23
CN1798769A (zh)	2006-07-05
ES2541134T3 (es)	2015-07-16

Publication	Publication Date	Title
PL2374819T3 (pl)	2017-09-29	Przeciwciała przeciwko MASP-2
EP1616881A4 (en)	2008-08-27	ANTI-MPL ANTIBODIES
PT1599504E (pt)	2015-03-02	Anticorpo modificado
GB0426043D0 (en)	2004-12-29	Antibodies
IL202681A0 (en)	2010-06-30	Interleukin-10 antibodies
EP1648512A4 (en)	2009-01-21	ANTI-CD19 ANTIBODIES
IL175773A0 (en)	2006-09-05	Anti-igfr1 antibody therapeutic combinations
GB0305702D0 (en)	2003-04-16	Bispecific antibodies
IL181575A0 (en)	2007-07-04	Anti-ox40l antibodies
GB0420044D0 (en)	2004-10-13	Antibodies to m-csf
IL228033A0 (en)	2013-09-30	Antibodies
IL173557A0 (en)	2006-07-05	Variable antibodies
SI1587542T1 (sl)	2012-10-30	Uporaba anti-cd100 protiteles
GB0420466D0 (en)	2004-10-20	Anti-glucan antibodies
AU2003218456A8 (en)	2003-10-20	Antibodies that specifically bind to gmad
EP1598368A4 (en)	2007-07-25	ANTI-PCI neutralizing ANTIBODY
ZA200701952B (en)	2008-10-29	Anti-OX40L antibodies
GB0306618D0 (en)	2003-04-30	Antibody
IL172511A0 (en)	2006-04-10	Specific human antibodies
GB0317974D0 (en)	2003-09-03	Novel antibodies
GB0329711D0 (en)	2004-01-28	Antibodies
GB0413479D0 (en)	2004-07-21	Novel antibodies
GB0319345D0 (en)	2003-09-17	Variable antibodies
GB0319118D0 (en)	2003-09-17	Variable antibodies
GB0217742D0 (en)	2002-09-11	Novel antibodies